Young adults' trajectories of Ecstasy use: A population based study

Addictive Behaviors

Volumn 38, Issue 11, 2013, Pages 2667-2674

  Smirnov, Andrew ^a,b   Najman, Jake M ^a   Hayatbakhsh, Reza ^a,c   Plotnikova, Maria ^a   Wells, Helene ^d   Legosz, Margot ^d   Kemp, Robert ^b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b QUEENSLAND HEALTH   (Australia)

^c Mt Isa Hospital   (Australia)

^d Crime and Misconduct Commission   (Australia)

Author keywords

Drug dependence; Drug use trajectories; Early adulthood; Ecstasy (MDMA); Maturational factors; Social environment

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE;

ADULT; AGGRESSION; ALCOHOL CONSUMPTION; ARTICLE; CANNABIS ADDICTION; DISTRESS SYNDROME; DRUG DEPENDENCE; DRUG USE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; METHAMPHETAMINE DEPENDENCE; POPULATION RESEARCH; PROSPECTIVE STUDY; SOCIAL ENVIRONMENT;

DRUG DEPENDENCE; DRUG USE TRAJECTORIES; EARLY ADULTHOOD; ECSTASY (MDMA); MATURATIONAL FACTORS; SOCIAL ENVIRONMENT;

AMPHETAMINE-RELATED DISORDERS; ATTITUDE TO HEALTH; CLUSTER ANALYSIS; HALLUCINOGENS; HUMANS; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; PERCEPTION; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; SOCIOECONOMIC FACTORS; STRESS, PSYCHOLOGICAL; YOUNG ADULT;

EID: 84881260783     PISSN: 03064603     EISSN: 18736327     Source Type: Journal    
DOI: 10.1016/j.addbeh.2013.06.018     Document Type: Article

References (57)

1. Abdallah A.B., Scheier L.M., Inciardi J.A., Copeland J., Cottler L.B. A psycho-economic model of ecstasy consumption and related consequences: A multi-site study with community samples. Substance Use & Misuse 2007, 42:1651-1684.
2. Achenbach T.M. Manual for the young adult self-report and young adult behavior checklist 1997, University of Vermont Department of Psychiatry, Burlington, VT.
3. Anthony J.C., Warner L.A., Kessler R.C. Comparative epidemiology of dependence on tobacco, alcohol, controlled substances, and inhalants: Basic findings from the national comorbidity survey. Experimental and Clinical Psychopharmacology 1994, 2:244-268.
4. Australian Electoral Commission Australian Electoral Commission Annual Report 2007-08 2008, Australian Electoral Commission, Canberra.
5. Australian Institute of Health and Welfare 2007 National Drug Strategy household survey: Detailed findings Australian Institute of Health and Welfare 2008, Canberra Australian Institute of Health and Welfare.
6. Baggott M.J. Preventing problems in Ecstasy users: Reduce use to reduce harm. Journal of Psychoactive Drugs 2002, 34:145-162.
7. Biezonski D.K., Meyer J.S. The nature of 3, 4-methylenedioxymethamphetamine (MDMA)-induced serotonergic dysfunction: Evidence for and against the neurodegeneration hypothesis. Current Neuropharmacology 2011, 9:84-90.
8. Bjelland I., Dahl A.A., Haug T.T., Neckelmann D. The validity of the Hospital Anxiety and Depression Scale. An updated literature review. Journal of Psychosomatic Research 2002, 52:69-77.
9. Boys A., Marsden J. Perceived functions predict intensity of use and problems in young polysubstance users. Addiction 2003, 98:951-963.
10. Brecht M.L., Huang D., Evans E., Hser Y.I. Polydrug use and implications for longitudinal research: Ten-year trajectories for heroin, cocaine, and methamphetamine users. Drug and Alcohol Dependence 2008, 96:193-201.
11. Breen C.L., Shakeshaft A.P., Doran C.M., Sanson-Fisher R.W., Mattick R.P. Cost-effectiveness of follow-up contact for a postal survey: A randomised controlled trial. Australian and New Zealand Journal of Public Health 2010, 34:508-512.
12. Bruno R., Matthews A., Degenhardt L., Gomez R. Ecstasy dependence: A different type of syndrome?. Neuropsychobiology 2009, 60:214-214.
13. Brunt T.M., Niesink R.J.M., van den Brink W. Impact of a transient instability of the ecstasy market on health concerns and drug use patterns in The Netherlands. The International Journal on Drug Policy 2012, 23:134-140.
14. Chen K., Kandel D.B. The natural history of drug use from adolescence to the mid-thirties in a general population sample. American Journal of Public Health 1995, 85:41-47.
15. Costantini M., Musso M., Viterbori P., Bonci F., Del Mastro L., Garrone O., et al. Detecting psychological distress in cancer patients: Validity of the Italian version of the Hospital Anxiety and Depression Scale. Supportive Care in Cancer 1999, 7:121-127.
16. Crawford J.R., Henry J.D., Crombie C., Taylor E.P. Normative data for the HADS from a large non-clinical sample. British Journal of Clinical Psychology 2001, 40:429-434.
17. Degenhardt L., Barker B., Topp L. Patterns of ecstasy use in Australia: Findings from a national household survey. Addiction (Abingdon, England) 2004, 99:187-195.
18. Degenhardt L., Bruno R., Topp L. Is ecstasy a drug of dependence?. Drug and Alcohol Dependence 2010, 107:1-10.
19. Ferdinand R.F., Verhulst F.C. The prediction of poor outcome in young-adults - comparison of the young-adult self-report, the general health questionnaire and the symptom checklist. Acta Psychiatrica Scandinavica 1994, 89:405-410.
20. Fernandez-Serrano M.J., Perez-Garcia M., Verdejo-Garcia A. What are the specific vs. generalized effects of drugs of abuse on neuropsychological performance?. Neuroscience and Biobehavioral Reviews 2011, 35:377-406.
21. Goudie A.J., Sumnall H.R., Field M., Clayton H., Cole J.C. The effects of price and perceived quality on the behavioural economics of alcohol, amphetamine, cannabis, cocaine, and ecstasy purchases. Drug and Alcohol Dependence 2007, 89:107-115.
22. Green A.R., King M.V., Shortall S.E., Fone K.C.F. Lost in translation: Preclinical studies on 3,4-methylenedioxymethamphetamine provide information on mechanisms of action, but do not allow accurate prediction of adverse events in humans. British Journal of Pharmacology 2012, 166:1523-1536.
23. Hamil-Luker J., Land K.C., Blau J. Diverse trajectories of cocaine use through early adulthood among rebellious and socially conforming youth. Social Science Research 2004, 33:300-321.
24. Haro J.M., Arbabzadeh-Bouchez S., Brugha T.S., De Girolamo G., Guyer M.E., Jin R., et al. Concordance of the Composite International Diagnostic Interview Version 3.0 (CIDI 3.0) with standardized clinical assessments in the WHO World Mental Health Surveys. International Journal of Methods in Psychiatric Research 2006, 15:167-180.
25. Healy M.J.R., Goldstein H. Regression to the mean. Annals of Human Biology 1978, 5:277-280.
26. Herrmann C. International experiences with the Hospital Anxiety and Depression Scale - a review of validation data and clinical results. Journal of Psychosomatic Research 1997, 42:17-41.
27. Hopper J.W., Su Z., Looby A.R., Ryan E.T., Penetar D.M., Palmer C.M., et al. Incidence and patterns of polydrug use and craving for ecstasy in regular ecstasy users: An ecological momentary assessment study. Drug and Alcohol Dependence 2006, 85:221-235.
28. Hser Y.I., Hamilton A., Niv N. Understanding drug use over the life course: Past, present, and future. Journal of Drug Issues 2009, 39:231-236.
29. Hser Y.I., Huang D., Brecht M.L., Li L.B., Evans E. Contrasting trajectories of heroin, cocaine, and methamphetamine use. Journal of Addictive Diseases 2008, 27:13-21.
30. Hser Y.I., Longshore D., Anglin M.D. The life course perspective on drug use - A conceptual framework for understanding drug use trajectories. Evaluation Review 2007, 31:515-547.
31. Huizink A.C., Ferdinand R.F., van der Ende J., Verhulst F.C. Symptoms of anxiety and depression in childhood and use of MDMA: Prospective, population based study. British Medical Journal 2006, 332:825-827.
32. Hunt G., Evans K., Moloney M., Bailey N. Combining different substances in the dance scene: Enhancing pleasure, managing risk and timing effects. Journal of Drug Issues 2009, 39:495-522. (495).
33. Jain A.K. Data clustering: 50years beyond K-means. Pattern Recognition Letters 2010, 31:651-666.
34. Kertesz S.G., Khodneva Y., Richman J., Tucker J.A., Safford M.M., Jones B., et al. Trajectories of Drug Use and Mortality Outcomes Among Adults Followed Over 18 Years. Journal of General Internal Medicine 2012, 27:808-816.
35. Kuypers K.P.C., Bosker W.M., Ramaekers J.G. Ecstasy, driving and traffic safety 2009.
36. Labouvie E. Maturing out of substance use: Selection and self-correction. Journal of Drug Issues 1996, 26:457-476.
37. Lieb R., Schuetz C.G., Pfister H., von Sydow K., Wittchen H. Mental disorders in ecstasy users: A prospective-longitudinal investigation. Drug and Alcohol Dependence 2002, 68:195-207.
38. Martins S.S., Mazzotti G., Chilcoat H.D. Trends in ecstasy use in the United States from 1995 to 2001: Comparison with marijuana users and association with other drug use. Experimental and Clinical Psychopharmacology 2005, 13:244-252.
39. Mohamed W.M.Y., Hamida S.B., Cassel J.-C., de Vasconcelos A.P., Jones B.C. MDMA: Interactions with other psychoactive drugs. Pharmacology, Biochemistry, and Behavior 2011, 99:759-774.
40. Morawska A., Oei T.P.S. Binge drinking in university students: A test of the cognitive model. Addictive Behaviors 2005, 30:203-218.
41. Müller C.P., Schumann G. Drugs as instruments: A new framework for non-addictive psychoactive drug use. The Behavioral and Brain Sciences 2011, 34:293-310.
42. Najman J.M., Hayatbakhsh M.R., McGee T.R., Bor W., O'Callaghan M.J., Williams G.M. The impact of puberty on aggression/delinquency: Adolescence to young adulthood. Australian and New Zealand Journal of Criminology 2009, 42:369-386.
43. Nichols D.E. Hallucinogens. Pharmacology & Therapeutics 2004, 101:131-181.
44. Nulsen C.E., Fox A.M., Hammond G.R. Differential effects of ecstasy on short-term and working memory: A meta-analysis. Neuropsychology Review 2010, 20:21-32.
45. Parrott A.C. Chronic tolerance to recreational MDMA (3,4-methylenedioxymethamphetamine) or Ecstasy. Journal of Psychopharmacology 2005, 19:71-83.
46. Peters G.-J.Y., Kok G. A structured review of reasons for ecstasy use and related behaviours: Pointers for future research. BMC Public Health 2009, 9.
47. Peters G.J., Kok G., Schaalma H.P. Careers in ecstasy use: Do ecstasy users cease of their own accord? Implications for intervention development. BMC Public Health 2008, 8:376.
48. Ramo D.E., Grov C., Delucchi K.L., Kelly B.C., Parsons J.T. Cocaine use trajectories of club drug-using young adults recruited using time-space sampling. Addictive Behaviors 2011, 36:1292-1300.
49. Robledo P. Cannabinoids, opioids and MDMA: Neuropsychological interactions related to addiction. Current Drug Targets 2010, 11:429-439.
50. Ryu E., Couper M.P., Marans R.W. Survey incentives: Cash vs. in-kind; face-to-face vs. mail; Response rate vs. nonresponse error. International Journal of Public Opinion Research 2006, 18:89-106.
51. Schenk S. MDMA self-administration in laboratory animals: A summary of the literature and proposal for future research. Neuropsychobiology 2009, 60:130-136.
52. Sindicich N., Burns L. Australian trends in ecstasy and related drug markets 2009: Findings from the Ecstasy and Related Drugs Reporting System (EDRS) 2010, National Drug and Alcohol Research Centre, University of NSW, Sydney, NSW.
53. Stout R.L. Commentary: Regression to the mean in addiction research. Addiction 2008, 103:53-53.
54. Verheyden S.L., Henry J.A., Curran H.V. Acute, sub-acute and long-term subjective consequences of 'ecstasy' (MDMA) consumption in 430 regular users. Human Psychopharmacology 2003, 18:507-517.
55. von Sydow K., Lieb R., Pfister H., Hofler M., Wittchen H.-U. Use, abuse and dependence of ecstasy and related drugs in adolescents and young adults - a transient phenomenon? Results from a longitudinal community study. Drug and Alcohol Dependence 2002, 66:147-159.
56. Williams R. Generalized ordered logit/partial proportional odds models for ordinal dependent variables. The Stata Journal 2006, 6:58-82.
57. Zigmond A.S., Snaith R.P. The hospital anxiety and depression scale. Acta Psychiatrica Scandinavica 1983, 67:361-370.